

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

208030Orig1s000

SUMMARY REVIEW

Summary Review for Regulatory Action

Date	(electronic stamp)
From	Edvardas Kaminskas, M.D.
Subject	Deputy Division Director Summary Review
NDA #	208030
Supplement #	
Applicant Name	ApoPharma, Inc.
Date of Submission	November 17, 2014
PDUFA Goal Date	September 17, 2015
Proprietary Name / Established (USAN) Name	Ferriprox Deferiprone
Dosage Forms / Strength	Oral Solution 50 g/500 mL (100 mg/mL)
Proposed Indications	For treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate
Action:	<i>Approval with No Change in Indication</i>

Material Reviewed/Consulted	
OND Action Package, including:	
Medical Officer Review	Andrew Dmytriuk, M.D./Kathy Robie-Suh, Ph.D., M.D.
Statistical Review	
Pharmacology Toxicology Review	Brenda J. Gehrke, Ph.D., Christopher M. Sheth, Ph.D.
CMC Review	Katherine Windsor, Ph.D./Donghao Lu, Ph.D./Lin Qi, Ph.D./Denise Miller, Ph.D./Zhong Li, Ph.D.
Clinical Pharmacology Review	Sriram Subramaniam, Ph.D./Bahru Habtemariam, Pharm.D.
OMP/DMPP	Morgan Walker, Pharm.D., M.B.A./LaShawn Griffiths, MSHS-PH, BSN/Sharon Mills, B.S.N
OSE/OMEPRM/DMEPA	Michelle Rutledge, Pharm.D./Yelena Maslov, Pharm.D.
OPDP	James Dvorsky, Pharm.D.
Division of New Drug Bioequivalence Evaluation/OSIS	John Kadavil, Ph.D./Charles R. Bonapace, Pharm.D.
CDTL Review	Janice Brown, M.S.

OND=Office of New Drugs
OMP=Office of Medical Policy
OSE= Office of Surveillance and Epidemiology
OPDP=Office of Prescription Drug Promotion
OMEPRM=Office of Medication Error Prevention and Risk Management
DMPP=Division of Medical Policy Programs
DMEPA=Division of Medication Error Prevention and Analysis
OSIS=Office of Study Integrity and Surveillance
CDTL=Cross-Discipline Team Leader

Signatory Authority Review Template

1. Introduction

Deferiprone is a small molecule iron chelator that was approved in 500 mg tablet form on October 14, 2011 “for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate” (NDA 21825). The current application is for Ferriprox (deferiprone) oral solution, submitted as a 505(b)(1) NDA with no change in the indication.

2. Background

Available treatments of patients with transfusional iron overload due to thalassemia syndromes are:

- Deferoxamine (Desferal®, Novartis Pharmaceuticals) powder for Injection Solution (NDA 16267) approved on April 1, 1968
- Deferasirox (Exjade®, Novartis Pharmaceuticals) tablets (NDA 21882) approved on November 2, 2005
- Deferiprone (Ferriprox®, ApoPharma) film-coated tablets (NDA 21825) approved on October 14, 2011
- Deferasirox (Jadenu®, Novartis Pharmaceuticals) film-coated tablets (NDA 206910) approved on March 30, 2015.

Since treatment of patients may start as early as 2 years of age (as in the indications for both formulations of deferasirox) and compliance with the drug regimens have been problematic for all of the above products, there is a need for a more acceptable formulation than the available tablets. This new formulation of Ferriprox, a 100 mg/mL oral solution was developed for patients who have difficulty taking the tablets.

The application contains CMC information for the oral solution and demonstration of bioequivalence of Ferriprox 100 mg/mL oral solution with the 500 mg tablet. A new NDA is submitted instead of a sNDA, since this is a new dosage form of deferiprone.

3. CMC/Device

The applicant cross-referenced the CMC information for deferiprone to DMF (b)(4). It was reviewed and was found to be adequate to support NDA 208030. Stability data of drug substance supports a retest period of (b)(4) months.

Ferriprox oral solution contains deferiprone (100 mg/mL), hydroxyethyl cellulose, glycerin, purified water, HCl, artificial cherry flavor, peppermint oil, and FD&C Yellow No. 6. The commercial production batch size is (b) (4). Ferriprox oral solution is manufactured by (b) (4).

into 500 mL amber polyethylene terephthalate round bottle and closed with a white polypropylene child-resistant cap with a foam liner. The nominal fill volume is (b) (4) mL. An expiration dating period of 18 months is granted for Ferriprox oral solution when stored at 20° to 25°C, protected from light. No product quality issues which preclude approval were found and the product quality review recommended approval of the NDA. No microbiology issues that preclude approval were found and the Microbiology Review recommended approval of the NDA. No facility issues that preclude approval were found and the facility review recommended approval of the NDA.

I concur with the conclusions reached by the chemistry reviewers regarding the acceptability of the manufacturing of the drug product and drug substance. Manufacturing site inspections were acceptable. Stability testing supports an expiry of 18 months. There are no outstanding issues.

4. Nonclinical Pharmacology/Toxicology

No new nonclinical information was submitted for this NDA submission. ApoPharma Inc. cross-referenced NDA 21825 for the pharmacology/toxicology studies for deferiprone. The nonclinical studies reviewed under NDA 21825 to support the initial approval of Ferriprox (deferiprone) provide sufficient information to support the use of Ferriprox (deferiprone) 100/mL oral solution for the same indication.

I concur with the conclusions reached by the pharmacology/toxicology reviewer that there are no outstanding pharmacology/toxicology issues that preclude approval

5. Clinical Pharmacology/Biopharmaceutics

The Sponsor submitted the results of relative bioavailability study of deferiprone oral solution and deferiprone 500 mg tablets. In study LA21-BA, the bioavailability of 3 x 500 mg tablets of Ferriprox relative to that of 1500 mg deferiprone administered as the oral solution (15 mL, 100 mg/mL) was determined under fasting conditions in 41 healthy adult volunteers (28 males and 13 females).

Study LA21-BE demonstrated that the relative bioavailability of ApoPharma's to-be-marketed deferiprone oral solution is comparable to the currently marketed Ferriprox 500 mg tablet, in that the primary PK parameters C_{max}, AUC(0-t), and AUC(0-∞) for the test product demonstrated bioequivalence (BE) against the Ferriprox tablet (see Table 1 below).

Table 1: Summary Bioequivalence Statistics, Study LA21-BE (n=41)

Parameter (unit)	Least Squares Geometric Mean		Ratio of Test / Reference	90% Confidence Interval of Ratio
	Feriprox Soln	Feriprox®		
AUC _{0-t} (h*ug/mL)	48.26	47.94	1.01	98.00 – 103.41
AUC _{0-∞} (h*ug/mL)	49.35	49.15	1.00	97.77 – 103.13
C _{max} (ug/mL)	18.90	19.23	0.98	88.91-108.67

A graphical representation of deferiprone concentrations is shown below in Figure 1 below.

The clinical pharmacology reviewers concluded that the BE study demonstrated the bioequivalence of ApoPharm's deferiprone oral solution and Feriprox® tablet.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.